BJA Advance Access originally published online on March 19, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
British Journal of Anaesthesia, 2004, Vol. 92, No. 5 675-680
© 2004 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry
1 Edinburgh Dental Institute, Lauriston Building, Lauriston Place, Edinburgh EH3 9YW, UK. 2 University Department Critical Care and Pain Medicine, The Royal Infirmary, Little France, Edinburgh EH16 9SU, UK
*Corresponding author. E-mail: iainandjulia{at}waitrose.com
Background. Rofecoxib, a selective cyclooxygenase-2 inhibitor, and dexketoprofen trometamol, a single isomer non-steroidal anti-inflammatory drug (NSAID), are available for the treatment of acute pain. Both are claimed to have fewer adverse effects than traditional NSAIDs. We have compared them in a clinical setting.
Methods. We performed a double-blind randomized controlled trial involving 120 patients undergoing surgical removal of a single mandibular third molar at the Edinburgh Dental Institute. Those who developed moderate pain within 4 h of the procedure were allocated to one of three groups: rofecoxib 50 mg (Group RO, n=37); dexketoprofen trometamol 25 mg (Group DE, n=42); or placebo (Group PL, n=41). Participants monitored pain intensity and pain relief for 24 h using visual analogue scales (VAS) and verbal rating scales (VRS). The summed, time-weighted pain relief score to 8 h derived from the VRS (TOTPAR 8) was used as the primary outcome variable.
Results. No significant difference was demonstrated between Groups RO and DE using TOTPAR 8 as the primary outcome variable. Both drugs were significantly different compared with placebo. Rescue analgesia during the trial period was required by only 15 out of 37 subjects in Group RO, but 35 out of 42 subjects in Group DE. The median times to use of rescue medication were 150 (Group PL), 398 (Group DE) and 1440 min (Group RO). Both drugs were well tolerated and adverse events reported were mild to moderate in severity.
Conclusions. Rofecoxib and dexketoprofen trometamol are effective treatments for acute pain using a dental pain model and are well tolerated. Rofecoxib has a longer duration of action as a single dose and gave adequate analgesia for over half of that study group; patients in the dexketoprofen trometamol group needed more rescue analgesia.
Br J Anaesth 2004; 92: 675–80
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Kleinert, C. Lange, A. Steup, P. Black, J. Goldberg, and P. Desjardins Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study Anesth. Analg., December 1, 2008; 107(6): 2048 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Huber and G. T. Terezhalmy The use of COX-2 inhibitors for acute dental pain: A second look J Am Dent Assoc, April 1, 2006; 137(4): 480 - 487. [Abstract] [Full Text] [PDF]
|
|